The Roadmap of AAV Treatment: From Induction to Maintenance

The standard of care for AAV is designed to be aggressive early on. Because the disease can cause rapid damage to vital organs like the kidneys and lungs, your medical team’s priority is to “put out the fire” quickly to prevent permanent scarring ^[1][2]. This process is divided into two clear stages: Induction and Maintenance.

Phase 1: Induction (Achieving Remission)

The goal of the induction phase is to stop active inflammation as quickly as possible. This phase typically lasts between 3 and 6 months ^[3].

For most patients (especially those with GPA and MPA), the current standard of care involves a combination of two types of medicine:

• Glucocorticoids (Steroids): These are used to immediately dampen the immune response ^[3]. While effective, high doses over long periods can cause significant side effects ^[4].
• Strong Immunosuppressants: You will likely receive either Rituximab (given via infusion) or Cyclophosphamide (given via infusion or pill) ^[3][5].
  • Rituximab is now frequently the preferred choice for many patients, especially those with the PR3-ANCA subtype, as it has a more favorable long-term safety profile ^[6][7].
  • Cyclophosphamide is still a highly effective option, particularly for severe cases. However, it carries significant risks of long-term toxicities, including bladder damage, secondary cancers, and infertility ^[8][9]. If this medication is recommended and you are of childbearing age, you should discuss fertility preservation with your doctor before starting treatment.

A Critical Warning on Infection Risk: The induction phase severely compromises your immune system. You will be highly susceptible to serious infections. It is standard of care for your doctor to prescribe preventative treatments—most notably, prophylactic antibiotics (such as Bactrim) to prevent a life-threatening lung infection called Pneumocystis jirovecii pneumonia (PJP) ^[3]. Ensure you are also up-to-date on recommended vaccines before starting induction, if possible.

The Role of Avacopan (Tavneos)

A major advancement in AAV care is the drug Avacopan. It is a “steroid-sparing” agent that targets the C5a receptor ^[10]. In clinical trials, patients taking Avacopan were able to significantly reduce their use of steroids while achieving the same—or even better—rates of remission and kidney recovery ^[11][4].

Treatment Variations for EGPA

If you have been diagnosed with EGPA, your treatment plan may look slightly different. While severe EGPA is treated similarly to GPA/MPA, many EGPA patients benefit significantly from IL-5 inhibitors (like mepolizumab). These drugs specifically target the eosinophils driving the inflammation and have become a major cornerstone of EGPA treatment ^[12][13].

Phase 2: Maintenance (Staying in Remission)

Once your symptoms are gone and your labs have stabilized, you enter the maintenance phase. This stage is focused on preventing the disease from returning (relapse) ^[5].

• Rituximab vs. Azathioprine: While both can be used, studies have shown that Rituximab is superior to Azathioprine at preventing relapses and keeping patients in remission longer ^[14][15].
• Duration: Maintenance therapy usually lasts at least 18 to 24 months, but your doctor may recommend a longer period based on your specific risk factors ^[16][17].

Ensuring Quality Care

Treatment for AAV should be closely monitored by a specialist (usually a rheumatologist or nephrologist). Because this is a rare disease, “standard of care” matters.

Warning Signs of Substandard Care:
If your doctor suggests staying on high-dose steroids (over 20mg of prednisone) for many months without a tapering plan, if they do not prescribe a prophylactic antibiotic during your induction phase, or if they do not discuss a long-term maintenance strategy after you reach remission, you should consider seeking a second opinion from a vasculitis specialist. Relapse is a significant concern, affecting approximately 25% of patients during maintenance; therefore, a clear, safe, and long-term strategy is essential ^[17].

Back to Home